article thumbnail

Bavtavirine

New Drug Approvals

Institute of Organic Chemistry and Biochemistry of the AS CR, v.v.i. Bavtavirine can be used for HIV disease research. Benzonitrile, 4-[[4-amino-8-[4-[(1 E )-2-cyanoethenyl]-2,6-dimethylphenyl]-2-quinazolinyl]amino]- Gilead Sciences, Inc.; Bavtavirine is a potent non-nucleoside reverse transcriptase inhibitors (NNRTIs).

article thumbnail

Women in Stem with Dr Emily Leproust

Drug Target Review

I started my journey in chemistry – first as an undergraduate and then in my PhD programme at the University of Houston, where I focused on organic chemistry and nucleic acids chemistry. They needed reference materials for the disease in order to develop and validate diagnostic tests.

DNA 116
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Antibody Drug Conjugates: windows of opportunity

Drug Target Review

In practice, some patients may be left managing a syndrome associated with the therapy along with the disease. In the ADC trial, the objective response rate (ORR) – defined as the percentage of patients whose disease decreased or disappears – was 42 percent whilst the ORR in the small molecule trial was 12.5

article thumbnail

Welcome to new Director David Hulcoop

The Open Targets Blog

After completing my PhD in organic chemistry at the University of Cambridge, I went to Canada as a Leverhulme Trust postdoctoral fellow. It’s a multi-dimensional, cross-disciplinary problem, requiring an understanding of genetics, of disease biology, and of drug discovery factors. I’m a chemist by training.

article thumbnail

How to Get Drugs Into the Brain

Drug Hunter

Obtaining adequate drug exposure in the brain is key to treating CNS diseases effectively. Prodrugs Remain in “Proof-of-Concept” Stages Prodrug strategies for CNS deliver have also been applied with varying success , with the most famous example being L-Dopa for Parkinson’s disease. Figure 18.

Drugs 206
article thumbnail

Marquis Who’s Who Honors David R. Elmaleh, PhD, with Inclusion in Who’s Who in the World

The Pharma Data

Elmaleh’s research has yielded compounds with potential in oncology, heart disease and neurodegenerative conditions, BOSTON, MA, October 23, 2020 /24-7PressRelease/ — Marquis Who’s Who, the world’s premier publisher of biographical profiles, is proud to honor David.

article thumbnail

test table sort

Broad Institute

He studies the genetics of numerous common diseases, particularly neuropsychiatric genetics especially schizophrenia, autism, and ADHD. His research focuses on the function of synapses and their disruption in animal models (especially non human primate models) of neurodevelopmental and psychiatric disease.